Interpace Biosciences, Inc. (OTCMKTS:IDXG) Short Interest Update

Interpace Biosciences, Inc. (OTCMKTS:IDXG) saw a large decline in short interest in August. As of August 14th, there was short interest totaling 91 shares, a decline of 80.7% from the July 30th total of 472 shares. Approximately 0.0% of the shares of the stock are short sold. Based on an average trading volume of 17,299 shares, the days-to-cover ratio is presently 0.0 days.

Interpace Biosciences Trading Down 0.7%

IDXG traded down $0.01 during midday trading on Wednesday, hitting $1.42. 100 shares of the company traded hands, compared to its average volume of 7,197. The business has a 50 day simple moving average of $1.59 and a two-hundred day simple moving average of $1.75. Interpace Biosciences has a 52-week low of $0.77 and a 52-week high of $2.40. The company has a market capitalization of $6.29 million, a price-to-earnings ratio of 17.75 and a beta of 0.61.

Interpace Biosciences (OTCMKTS:IDXG) last released its earnings results on Monday, August 10th. The business services provider reported $0.01 EPS for the quarter. Interpace Biosciences had a net margin of 67.64% and a return on equity of 145.40%. The business had revenue of $9.13 million during the quarter.

Interpace Biosciences Company Profile

Interpace Biosciences, Inc provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer.